Candriam S.C.A. Theravance Biopharma, Inc. Transaction History

Candriam S.C.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$9.87 - $11.44 $382,097 - $442,876	-38,713 Reduced 46.53%	44,489 $482,000
Q4 2022 Feb 13, 2023	SELL	$9.65 - $11.34 $189,390 - $222,558	-19,626 Reduced 19.09%	83,202 $933,000
Q3 2022 Nov 10, 2022	BUY	$8.39 - $10.22 $862,726 - $1.05 Million	102,828 New	102,828 $1.04 Million
Q3 2021 Nov 09, 2021	SELL	$6.77 - $14.41 $3.22 Million - $6.85 Million	-475,696 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$14.52 - $22.46 $6.91 Million - $10.7 Million	475,696 New	475,696 $6.91 Million
Q2 2020 Jul 23, 2020	SELL	$20.64 - $30.69 $5.73 Million - $8.52 Million	-277,700 Closed	0 $0
Q4 2019 Jan 21, 2020	SELL	$16.12 - $25.89 $32,240 - $51,780	-2,000 Reduced 0.72%	277,700 $7,000
Q4 2018 Feb 14, 2019	BUY	$22.52 - $35.07 $563,000 - $876,750	25,000 Added 9.82%	279,700 $7.16 Million
Q3 2018 Nov 07, 2018	BUY	$22.83 - $32.67 $5.81 Million - $8.32 Million	254,700 New	254,700 $8.32 Million
Q4 2017 Feb 07, 2018	SELL	$25.82 - $35.66 $516,400 - $713,199	-20,000 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$23.88 - $34.96 $477,600 - $699,200	20,000	20,000 $685,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.